Celularity Dismisses Chief Commercial Officer as Nasdaq Delisting Crisis Deepens
CELU sits 25% above its 52-week low of $0.56 on light trading volume (0.1× avg).
Summary
Celularity fired its Chief Commercial Officer Rick Gonzalez after only two months on the job, adding leadership turmoil to an already dire situation with Nasdaq delisting threats and a cash crunch.
Key Events · Executive and Board Changes · CELU
-
CCO Terminated After 2 Months
Rick Gonzalez, who was appointed Chief Commercial Officer on June 3, 2026, was terminated effective August 5, 2026. No reason was provided for the dismissal.
-
Leadership Void During Crisis
The departure leaves the commercial function without a leader while the company confronts two Nasdaq delisting notices (market value and bid price) and a cash runway measured in weeks following a $1 million bridge loan.
-
No Successor Named
The filing does not announce a replacement or any interim leadership plan for the commercial organization.
Analysis · CELU · Life Sciences
Effective August 5, 2026, Celularity terminated Chief Commercial Officer Rick Gonzalez, just two months after his appointment. The move unfolds against a backdrop of severe liquidity and compliance pressures — the company is grappling with two active Nasdaq delisting notices (market value and bid price) and recently secured a $1 million bridge loan due in 30 days. Losing the commercial lead at this critical juncture casts doubt on the company's go-to-market strategy and overall stability.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.3M. The 52-week trading range was $0.56 to $4.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.